West Family Investments Inc. Buys 1,643 Shares of AstraZeneca PLC (NASDAQ:AZN)

West Family Investments Inc. raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 12.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,920 shares of the company’s stock after buying an additional 1,643 shares during the period. West Family Investments Inc.’s holdings in AstraZeneca were worth $1,162,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. State Board of Administration of Florida Retirement System bought a new position in shares of AstraZeneca in the 1st quarter worth about $1,524,000. O Shaughnessy Asset Management LLC boosted its position in AstraZeneca by 17.9% in the first quarter. O Shaughnessy Asset Management LLC now owns 111,659 shares of the company’s stock worth $7,565,000 after purchasing an additional 16,966 shares during the last quarter. Atlanta Consulting Group Advisors LLC purchased a new position in shares of AstraZeneca during the 1st quarter valued at about $225,000. Lake Street Advisors Group LLC lifted its stake in shares of AstraZeneca by 32.8% during the 1st quarter. Lake Street Advisors Group LLC now owns 11,177 shares of the company’s stock valued at $757,000 after buying an additional 2,763 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its holdings in AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after acquiring an additional 146 shares during the period. 20.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

AZN has been the subject of several research analyst reports. TD Cowen raised their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Trading Up 0.3 %

Shares of NASDAQ AZN opened at $63.39 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business’s 50 day moving average is $74.68 and its two-hundred day moving average is $78.15. The stock has a market capitalization of $196.55 billion, a P/E ratio of 30.33, a PEG ratio of 1.17 and a beta of 0.47. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter last year, the firm posted $0.87 earnings per share. The business’s revenue was up 18.0% compared to the same quarter last year. As a group, research analysts expect that AstraZeneca PLC will post 4.07 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.